IL231448A0 - Phosphatidylinositol 3-kinase inhibitors for cancer treatment - Google Patents

Phosphatidylinositol 3-kinase inhibitors for cancer treatment

Info

Publication number
IL231448A0
IL231448A0 IL231448A IL23144814A IL231448A0 IL 231448 A0 IL231448 A0 IL 231448A0 IL 231448 A IL231448 A IL 231448A IL 23144814 A IL23144814 A IL 23144814A IL 231448 A0 IL231448 A0 IL 231448A0
Authority
IL
Israel
Prior art keywords
phosphatidylinositol
cancer
treatment
kinase inhibitors
kinase
Prior art date
Application number
IL231448A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Sa
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Exelixis Inc filed Critical Sanofi Sa
Publication of IL231448A0 publication Critical patent/IL231448A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL231448A 2011-09-14 2014-03-11 Phosphatidylinositol 3-kinase inhibitors for cancer treatment IL231448A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161534836P 2011-09-14 2011-09-14
US201161543529P 2011-10-05 2011-10-05
US201161562670P 2011-11-22 2011-11-22
PCT/US2012/055387 WO2013040337A1 (en) 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL231448A0 true IL231448A0 (en) 2014-04-30

Family

ID=46940622

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231448A IL231448A0 (en) 2011-09-14 2014-03-11 Phosphatidylinositol 3-kinase inhibitors for cancer treatment

Country Status (10)

Country Link
EP (1) EP2755654A1 (enExample)
KR (1) KR20140077911A (enExample)
AU (1) AU2012308414A1 (enExample)
BR (1) BR112014005858A2 (enExample)
CA (1) CA2848724A1 (enExample)
IL (1) IL231448A0 (enExample)
IN (1) IN2014CN02671A (enExample)
TW (1) TW201325592A (enExample)
UY (1) UY34339A (enExample)
WO (1) WO2013040337A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754565B (zh) * 2021-11-09 2022-02-22 南京威凯尔生物医药科技有限公司 一种连续流微反应器中制备沙库巴曲中间体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
EP1940839B1 (en) 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
RS53020B (sr) * 2007-04-11 2014-04-30 Exelixis Inc. Kombinovane terapije koje sadrže hinoksalin inhibitor pi3k-alfa za upotrebu u lečenju kancera
WO2010146391A1 (en) * 2009-06-15 2010-12-23 Generics [Uk] Limited Regioselective synthesis of letrozole
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
IN2014CN02671A (enExample) 2015-07-03
WO2013040337A1 (en) 2013-03-21
TW201325592A (zh) 2013-07-01
WO2013040337A9 (en) 2014-04-03
UY34339A (es) 2013-04-30
CA2848724A1 (en) 2013-03-21
BR112014005858A2 (pt) 2017-06-13
EP2755654A1 (en) 2014-07-23
KR20140077911A (ko) 2014-06-24
AU2012308414A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
HUS2200017I1 (hu) Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
IL232128B (en) Tor kinase inhibitors for cancer treatment
AP3847A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
IL238400A0 (en) Triazolopyrazines as brd4 inhibitors for use in cancer therapy
SI2753334T1 (sl) Fap-aktivirani proteasomski inhibitorji za zdravljenje solidnih tumorjev
SI2523661T1 (sl) Nkcc inhibitorji za zdravljenje avtizma
IL231835A0 (en) Pyrrolopyrimidine compounds for cancer treatment
IL232530B (en) A combination of factors for cancer treatment
EP2751267A4 (en) METHOD FOR THE TREATMENT OF BREAST CANCER
IL228719A0 (en) parp inhibitors for the treatment of cipn
SG10201502566SA (en) Use of novel pan-cdk inhibitors for treating tumors
PL2817286T3 (pl) Inhibitory kinazy do leczenia raka
IL275636A (en) Medical combination for cancer treatment
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
IL231448A0 (en) Phosphatidylinositol 3-kinase inhibitors for cancer treatment
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer
ZA201405068B (en) Piperazinyl derivatives for the treatment of cancer
HK1194970A (en) Parp inhibitors for the treatment of cipn